Stock VNDA VANDA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Real-time Estimate Cboe BZX
Other stock markets
 02:17:28 2024-05-17 pm EDT 		5-day change 1st Jan Change
5.51 USD -1.25% Intraday chart for Vanda Pharmaceuticals Inc. +9.62% +30.92%
May. 15 Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results MT
May. 15 Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results
MT
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
PR
Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness
CI
Transcript : Vanda Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024
Vanda: Q1 Earnings Snapshot
AQ
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M
MT
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
PR
Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading
MT
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
MT
Sector Update: Health Care
MT
Vanda Pharmaceuticals Shares Rise After Future Pak Adds $260 Million Potential Payments to Cash Offer
MT
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
PR
Future Pak sweetens buyout offer for Vanda Pharmaceuticals
RE
Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
PR
Vanda Strikes Out At The Supreme Court
AQ
Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer
RE
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
AQ
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ ANDA Litigation
AQ
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. News Vanda Pharmaceuticals Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW